Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (STTK) on January 22, 2026. The report discloses the entry into a Material Definitive Agreement regarding a new equity financing arrangement.
Key Financial Metrics and Transaction Details
- Transaction Type: At-the-market (ATM) equity sales agreement.
- Maximum Offering Size: Up to $75,000,000 of common stock.
- Agent: Leerink Partners LLC.
- Commission: Up to 3.0% of the gross sales price of shares sold.
- Use of Proceeds: Advancing ongoing and planned clinical trials, developing additional product candidates, working capital, and general corporate purposes.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period.
Material Changes
The primary material change is the establishment of a mechanism to sell up to $75 million in equity. The Company has no obligation to sell any shares and may suspend or terminate the agreement at any time. The Registration Statement on Form S-3 was declared effective by the SEC on January 21, 2026.
Outlook, Risks, and Management Commentary
Management intends to utilize the proceeds to support clinical development and general operations. The agreement includes standard termination rights for both parties, including termination by the Agent in the event of a material adverse effect that could impair the ability to sell shares. The filing explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of a $75 million offering.
- Confirm the status of the Form S-3 Registration Statement (File No. 333-292697) and the effective date of January 21, 2026.
- Review the full Sales Agreement (Exhibit 1.1) for specific termination clauses and expense reimbursement terms.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.